Iipayipi

I-R&D ye-Sorrento igxile ekuqhubeni izinto ezintsha kwi-COVID-19, unyango lomhlaza, ulawulo olupheleleyo lweentlungu kunye nezifo ezizimelayo.

IiNkqubo eziPhambili Ukubonisa Ulungelelaniso Isigaba I Isigaba II Isigaba III/engundoqo Ukuvunyelwa kwe-FDA
Iinkqubo ze-COVID-19  

COVISTIX™ (uxilongo) Uvavanyo lweAntigen olukhawulezayo

*

Ugunyaziso lokuSebenzisa oluNgxamisekileyo (EUA) eMexico (COFEPRIS), eBrazil (ANVISA), kunye neCE Ephawulwe eYurophu

COVIMARK™ (uxilongo) Uvavanyo lweAntigen olukhawulezayo

*

Isicelo singeniswe e-US naseKhanada kuGunyaziso lokuSebenzisa oluNgxamisekileyo (EUA)

COVISHIELD™ (unyango) I-Antibody engathathi hlangothi (IN) kwiZigulana eziNgaphandle nakwizigulana ezilaliswayo

40%*

COVISHIELD™ (unyango) I-Antibody engathathi hlangothi (IV) kwiZigulana eziNgaphandle nakwizigulana ezilaliswayo

20%*

FUJOVEE™ (Abivertinib) Emandundu COVID-19 kwizigulana zase-ICU

82%*

Uvavanyo olungundoqo olulindele uCwangciso lwe-FDA

OQORY™ (COVI-MSC) I-ARDS ngenxa ye-COVID-19 kwizigulana zase-ICU

82%*

Uvavanyo olubalulekileyo eBrazil

Mpro Isithinteli (ipilisi yomlomo) Anti-intsholongwane

40%*

Ugonyo lwe-Omicron mRNA Igciwane

20%*

IiNkqubo eziPhambili Ukubonisa Ulungelelaniso Isigaba I Isigaba II Isigaba III/engundoqo Ukuvunyelwa kwe-FDA
immunotherapy  

FUJOVEE™ (Abivertinib) I-NSCLC

82%*

FUJOVEE™ (Abivertinib) B IiLymphomas zeeseli

60.2%*

FUJOVEE™ (Abivertinib) Prostate

20%*

FUJOVEE™ (Abivertinib) Lupus

20%*

FUJOVEE™ (Abivertinib) MS

20%*

FUJOVEE™ (Abivertinib) I-GvHD

20%*

PD-L1 (Socazolimab)* I-SCLC

82%*

*Ngentsebenziswano neLee's Pharm eTshayina

I-PD-L1 (STI-3031)** Ngomhlaza wesibeleko

82%*

**E-US kunye nentsebenziswano ne-ImmuneOncia eKorea

CD47 Amathumba aqinileyo

40%*

I-CD38 DAR-T Multiel Myeloma

40%*

CD38 ADC I-Amyloidosis, i-Myeloma emininzi, i-T-ALL, kunye ne-esophageal

40%*

TROP2 ADC* Amathumba aqinileyo

40%*

* ETshayina

Intsholongwane kaSeprehvec™ oncolytic Amathumba aqinileyo; CNS Amathumba

40%*

BCMA ADC Amathumba olwelo

20%*

Bevacizumab-ADAB™ Umhlaza weSifo seNtsholongwane

40%*

Ngentsebenziswano neMayo Clinic

Bevacizumab-ADAB™ I-Ovarian Cancer

40%*

Ngentsebenziswano neMayo Clinic

I-Rituximab-ADAB™ I-B-cell Lymphomas

40%*

Ngentsebenziswano neMayo Clinic
IiNkqubo eziPhambili Ukubonisa Ulungelelaniso Isigaba I Isigaba II Isigaba III/engundoqo Ukuvunyelwa kwe-FDA
Ubuhlungu  

I-ZTlido™ 1.8%
I-Posterpetic Neuralgia - PHN

99.8%*

I-SP-102 (SEMDEXA) I-Lumbar Radicular / Sciatica Pain

82%*

I-SP-103 (I-Lidocaine Topical System 5.4%) Ubuhlungu be-Acute back

20%*

I-SP-104 (Idosi eLityazisiweyo yokuGqiswa kweNaltrexone) Fibromyalgia

20%*

I-RTX (i-resiniferatoxin)
Isitofu se-epidural
Intlungu engenakunyanzeliswa kwi-Cancer Advanced

60.3%*

Ukubizwa kwenkedama

I-RTX (i-resiniferatoxin)
Indlela ye-Intra-articular
Iintlungu ze-OA zedolo eliPhakathi ukuya kutsho kweMandundu

60.2%*

IiNkqubo eziPhambili Ukubonisa Ulungelelaniso Isigaba I Isigaba II Isigaba III/engundoqo Ukuvunyelwa kwe-FDA
Ukuhanjiswa kweLymphatic  

Sofusa® I-anti-TNF Amajoni omzimba (RA)

40%*

Sofusa® i-anti-PD-1 I-Cutaneous T-Cell Lymphoma (CTCL)

40%*

Sofusa® anti-CTLA-4 IMelanoma

40%*

Ngentsebenziswano neMayo Clinic
Iinkqubo ze-COVID-19
IiNkqubo eziPhambili (Isalathiso) Isigaba
COVISTIX™ (uxilongo) FDA EUA
COVIMARK™ (uxilongo) FDA EUA
COVISHIELD™ (unyango) PH I
COVISHIELD™ (unyango) Ulungelelaniso
FUJOVEE™ (Abivertinib) Ph III
OQORY™ (COVI-MSC) Ph III
I-Mpro Inhibitor (ipilisi yomlomo) (anti-viral) Ph I
Ugonyo lwe-Omicron mRNA (isitofu) Ulungelelaniso
immunotherapy
IiNkqubo eziPhambili (Isalathiso) Isigaba
FUJOVEE™ (Abivertinib) (NSCLC) Ph III
FUJOVEE™ (Abivertinib) (B Cell Lymphomas) Ph II
FUJOVEE™ (Abivertinib) (Prostate) Ulungelelaniso
FUJOVEE™ (Abivertinib) (Lupus) Ulungelelaniso
FUJOVEE™ (Abivertinib) (NKSK) Ulungelelaniso
FUJOVEE™ (Abivertinib) (GvHD) Ulungelelaniso
PD-L1 (Socazolimab)*(SCLC) Ph III
I-PD-L1 (STI-3031)** (Umhlaza woMlomo weSibeleko) Ph III
CD47 (Iithumba eziqinileyo) Ph I
I-CD38 DAR-T (Multiple Myeloma) Ph I
CD38 ADC (I-Amyloidosis, i-Myeloma emininzi, i-T-ALL, kunye ne-esophageal) Ph I
TROP2 ADC* (Iithumba eziqinileyo) Ph I
Intsholongwane kaSeprehvec™ oncolytic (Iithumba eziqinileyo; CNS Tumors) PH I
BCMA ADC (Amathumba olwelo) Ulungelelaniso
Bevacizumab-ADAB™ (Umhlaza we-Endometrial) Ph I
Bevacizumab-ADAB™ (Umhlaza wesibeleko) Ph I
I-Rituximab-ADAB™ (B-cell Lymphomas) Ph I
Ubuhlungu
IiNkqubo eziPhambili (Isalathiso) Isigaba
I-ZTlido™ 1.8% (I-Postherpetic Neuralgia - PHN) Ukuvunyelwa kwe-FDA
I-SP-102 (SEMDEXA) Ph III
I-SP-103 (I-Lidocaine Topical System 5.4%) Ulungelelaniso
I-SP-104 (Idosi eLityazisiweyo yokuGqiswa kweNaltrexone) Ulungelelaniso
I-RTX (resiniferatoxin) inaliti ye-epidural (Iintlungu ezinganyangekiyo kuMhlaza oPhezulu) Ph II
I-RTX (resiniferatoxin) Indlela ye-intra-articular (Iintlungu zedolo eliphakathi ukuya kweOA kakhulu) Ph II
Ukuhanjiswa kweLymphatic
IiNkqubo eziPhambili (Isalathiso) Isigaba II
Sofusa® I-anti-TNF (Autoimmune RA) Ph I
Sofusa® i-anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL)) Ph I
Sofusa® anti-CTLA-4 (Imelanoma) Ph I